Abstract: Single-agent Ibrutinib 420mg Induces Durable Responses in Patients with CLL

Abstract: Single-agent Ibrutinib 420mg Induces Durable Responses in Patients with CLL

HMP CME

4 years
318 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
Up Next Autoplay